Frelii Speaks with Potential Partners at CES about the Future of AI in DNA Sequencing and Analysis
Summary
“The rapid evolution of AI-based DNA sequencing is delivering new insight into the genome coupled with connections and patterns of gene expression at a scale we have never seen before,” said Ian Jenkins, CEO of Frelii. Companies are turning to Frelii expertise because with its AI, DNA sequencing and analysis can be completed in a matter of hours, as opposed to weeks or months and at a level that expands the frontiers of knowledge by analyzing massive amounts of data. Most consumer DNA kits on the market look at 400,000 to 700,000 data points along the genome, generating approximately 384 outcomes, such as ancestry, diet suggestions or identification of potential health risks. “AI combined with DNA sequencing is a match made in heaven because it can bring to light previously unexplored connections that can impact entire industries such as the rapidly expanding medical marijuana market to health care at large,” Jenkins said. Frelii is investing in its AI to empower medical professionals when seeking to provide, where it is legal, precision dosing of THC, CBD, CBN and terpenes from appropriate strains of cannabis via the right delivery format.